{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:17:10Z","timestamp":1791821830327,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11606-020-06251-w","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T18:02:51Z","timestamp":1604685771000},"page":"964-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy Changes"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9208-1490","authenticated-orcid":false,"given":"Ajay","family":"Manhapra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Ross","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"10100","key":"6251_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/s0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100):1211-59. https:\/\/doi.org\/10.1016\/s0140-6736(17)32154-2","journal-title":"Lancet"},{"issue":"8","key":"6251_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jpain.2015.05.002","volume":"16","author":"RL Nahin","year":"2015","unstructured":"Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 2015;16(8):769-80. https:\/\/doi.org\/10.1016\/j.jpain.2015.05.002","journal-title":"J Pain"},{"issue":"2","key":"6251_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","volume":"20","author":"MH Pitcher","year":"2019","unstructured":"Pitcher MH, Von Korff M, Bushnell MC, Porter L. Prevalence and Profile of High-Impact Chronic Pain in the United States. J Pain 2019;20(2):146-60. https:\/\/doi.org\/10.1016\/j.jpain.2018.07.006","journal-title":"J Pain"},{"issue":"1","key":"6251_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mcna.2015.08.012","volume":"100","author":"R Dale","year":"2016","unstructured":"Dale R, Stacey B. Multimodal Treatment of Chronic Pain. Med Clin North Am 2016;100(1):55-64. https:\/\/doi.org\/10.1016\/j.mcna.2015.08.012","journal-title":"Med Clin North Am"},{"issue":"9","key":"6251_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2018.0899","volume":"319","author":"EE Krebs","year":"2018","unstructured":"Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872-82. https:\/\/doi.org\/10.1001\/jama.2018.0899","journal-title":"JAMA."},{"issue":"5","key":"6251_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/pds.4278","volume":"27","author":"R Mojtabai","year":"2018","unstructured":"Mojtabai R. National trends in long-term use of prescription opioids. Pharmacoepidemiol Drug Saf 2018;27(5):526-34. https:\/\/doi.org\/10.1002\/pds.4278","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"6251_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1er","volume":"65","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain \u2014 United States, 2016. MMWR Recommend Rep. 2016;65(1):1-49. https:\/\/doi.org\/10.15585\/mmwr.rr6501e1er","journal-title":"MMWR Recommend Rep"},{"issue":"2","key":"6251_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1155\/2004\/605328","volume":"9","author":"H Merskey","year":"2004","unstructured":"Merskey H. Pain disorder, hysteria or somatization? Pain Res Manag 2004;9(2):67-71.","journal-title":"Pain Res Manag"},{"issue":"17","key":"6251_CR9","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/archinternmed.2012.3212","volume":"172","author":"JC Ballantyne","year":"2012","unstructured":"Ballantyne JC, Sullivan MD, Kolodny A. Opioid Dependence vs Addiction: A Distinction Without a Difference? Arch Intern Med 2012;172(17):1342-3. https:\/\/doi.org\/10.1001\/archinternmed.2012.3212","journal-title":"Arch Intern Med"},{"issue":"4","key":"6251_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","volume":"156","author":"KE Vowles","year":"2015","unstructured":"Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-76. https:\/\/doi.org\/10.1097\/01.j.pain.0000460357.01998.f1","journal-title":"Pain."},{"key":"6251_CR11","doi-asserted-by":"publisher","unstructured":"Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary. Subst Abuse 2017:1-10. https:\/\/doi.org\/10.1080\/08897077.2017.1381663","DOI":"10.1080\/08897077.2017.1381663"},{"issue":"1","key":"6251_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/j.pain.0000000000000730","volume":"158","author":"PD Quinn","year":"2017","unstructured":"Quinn PD, Hur K, Chang Z, Krebs EE, Bair MJ, Scott EL, et al. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims. Pain. 2017;158(1):140-8. https:\/\/doi.org\/10.1097\/j.pain.0000000000000730","journal-title":"Pain."},{"key":"6251_CR13","unstructured":"Oregon Pain Guidance- Tapering- Guidance and tools. 2018. https:\/\/www.oregonpainguidance.org\/guideline\/tapering\/."},{"issue":"12","key":"6251_CR14","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1097\/j.pain.0000000000001680","volume":"160","author":"JC Ballantyne","year":"2019","unstructured":"Ballantyne JC, Sullivan MD, Koob GF. Refractory dependence on opioid analgesics. Pain. 2019;160(12):2655-60. https:\/\/doi.org\/10.1097\/j.pain.0000000000001680","journal-title":"Pain."},{"key":"6251_CR15","unstructured":"Ballantyne JC, Stannard C. New addiction criteria: diagnostic challenges persist in treating pain with opioids. Pain. 2013;1."},{"issue":"12","key":"6251_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","volume":"78","author":"MP Davis","year":"2018","unstructured":"Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs. 2018;78(12):1211-28. https:\/\/doi.org\/10.1007\/s40265-018-0953-z","journal-title":"Drugs."},{"issue":"12","key":"6251_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/pme.12520","volume":"15","author":"D Daitch","year":"2014","unstructured":"Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J, Jr. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med (Malden, Mass). 2014;15(12):2087-94. https:\/\/doi.org\/10.1111\/pme.12520","journal-title":"Pain Med (Malden, Mass)"},{"issue":"6","key":"6251_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5055\/jom.2012.0137","volume":"8","author":"A Rosenblum","year":"2012","unstructured":"Rosenblum A, Cruciani RA, Strain EC, Cleland CM, Joseph H, Magura S, et al. Sublingual buprenorphine\/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8(6):369-82. https:\/\/doi.org\/10.5055\/jom.2012.0137","journal-title":"J Opioid Manag"},{"key":"6251_CR19","doi-asserted-by":"publisher","unstructured":"Neumann AM, Blondell RD, Hoopsick RA, Homish GG. Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. J Addict Dis 2019:1-9. https:\/\/doi.org\/10.1080\/10550887.2019.1690929","DOI":"10.1080\/10550887.2019.1690929"},{"issue":"suppl_1","key":"6251_CR20","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/pm\/pny086","volume":"19","author":"BJ Oldfield","year":"2018","unstructured":"Oldfield BJ, Edens EL, Agnoli A, Bone CW, Cervone DJ, Edmond SN, et al. Multimodal Treatment Options, Including Rotating to Buprenorphine, Within a Multidisciplinary Pain Clinic for Patients on Risky Opioid Regimens: A Quality Improvement Study. Pain Med (Malden, Mass). 2018;19(suppl_1):S38-S45. https:\/\/doi.org\/10.1093\/pm\/pny086","journal-title":"Pain Med (Malden, Mass)"},{"key":"6251_CR21","unstructured":"US Department of Health and Human Services. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics. https:\/\/www.hhs.gov\/opioids\/treatment\/clinicians-guide-opioid-dosage-reduction\/index.html."},{"issue":"3","key":"6251_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejpain.2005.05.003","volume":"10","author":"A Rhodin","year":"2006","unstructured":"Rhodin A, Gronbladh L, Nilsson LH, Gordh T. Methadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-up. Eur J Pain 2006;10(3):271-8. https:\/\/doi.org\/10.1016\/j.ejpain.2005.05.003","journal-title":"Eur J Pain"},{"issue":"4","key":"6251_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1037\/0033-2909.133.4.581","volume":"133","author":"RJ Gatchel","year":"2007","unstructured":"Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007;133(4):581-624. https:\/\/doi.org\/10.1037\/0033-2909.133.4.581","journal-title":"Psychol Bull"},{"issue":"2","key":"6251_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1037\/a0035747","volume":"69","author":"DM Ehde","year":"2014","unstructured":"Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol 2014;69(2):153-66. https:\/\/doi.org\/10.1037\/a0035747","journal-title":"Am Psychol"},{"issue":"2","key":"6251_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1037\/a0035623","volume":"69","author":"LM McCracken","year":"2014","unstructured":"McCracken LM, Vowles KE. Acceptance and commitment therapy and mindfulness for chronic pain: model, process, and progress. Am Psychol 2014;69(2):178-87. https:\/\/doi.org\/10.1037\/a0035623","journal-title":"Am Psychol"},{"issue":"10","key":"6251_CR26","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nn.3811","volume":"17","author":"E Navratilova","year":"2014","unstructured":"Navratilova E, Porreca F. Reward and motivation in pain and pain relief. Nat Neurosci 2014;17(10):1304-12. https:\/\/doi.org\/10.1038\/nn.3811","journal-title":"Nat Neurosci"},{"issue":"8","key":"6251_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1037\/0003-066X.35.8.691","volume":"35","author":"RL Solomon","year":"1980","unstructured":"Solomon RL. The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am Psychol 1980;35(8):691-712.","journal-title":"Am Psychol"},{"issue":"7","key":"6251_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1526-4637.2010.00881.x","volume":"11","author":"J Shurman","year":"2010","unstructured":"Shurman J, Koob GF, Gutstein HB. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med (Malden, Mass). 2010;11(7):1092-8. https:\/\/doi.org\/10.1111\/j.1526-4637.2010.00881.x","journal-title":"Pain Med (Malden, Mass)"},{"key":"6251_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejphar.2014.11.044","volume":"753","author":"GF Koob","year":"2015","unstructured":"Koob GF. The dark side of emotion: the addiction perspective. Eur J Pharmacol 2015;753:73-87. https:\/\/doi.org\/10.1016\/j.ejphar.2014.11.044","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"6251_CR30","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016;3(8):760-73. https:\/\/doi.org\/10.1016\/s2215-0366(16)00104-8","journal-title":"Lancet Psychiatry"},{"key":"6251_CR31","doi-asserted-by":"publisher","first-page":"m283","DOI":"10.1136\/bmj.m283","volume":"368","author":"EM Oliva","year":"2020","unstructured":"Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020;368:m283. https:\/\/doi.org\/10.1136\/bmj.m283","journal-title":"BMJ."},{"issue":"10","key":"6251_CR32","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1097\/j.pain.0000000000001315","volume":"159","author":"S McPherson","year":"2018","unstructured":"McPherson S, Lederhos Smith C, Dobscha SK, Morasco BJ, Demidenko MI, Meath THA, et al. Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. Pain. 2018;159(10):2097-104. https:\/\/doi.org\/10.1097\/j.pain.0000000000001315","journal-title":"Pain."},{"issue":"10","key":"6251_CR33","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/pme.12812","volume":"16","author":"P Harden","year":"2015","unstructured":"Harden P, Ahmed S, Ang K, Wiedemer N. Clinical Implications of Tapering Chronic Opioids in a Veteran Population. Pain Med (Malden, Mass). 2015;16(10):1975-81. https:\/\/doi.org\/10.1111\/pme.12812","journal-title":"Pain Med (Malden, Mass)"},{"issue":"12","key":"6251_CR34","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s11606-019-05301-2","volume":"34","author":"JR James","year":"2019","unstructured":"James JR, Scott JM, Klein JW, Jackson S, McKinney C, Novack M, et al. Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. J Gen Intern Med 2019;34(12):2749-55. https:\/\/doi.org\/10.1007\/s11606-019-05301-2","journal-title":"J Gen Intern Med"},{"key":"6251_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jsat.2019.05.001","volume":"103","author":"TL Mark","year":"2019","unstructured":"Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abus Treat 2019;103:58-63. https:\/\/doi.org\/10.1016\/j.jsat.2019.05.001","journal-title":"J Subst Abus Treat"},{"key":"6251_CR36","unstructured":"FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. FDA Drug Safety Communication. 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Accessed June 2, 2020."},{"issue":"24","key":"6251_CR37","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMp1904190","volume":"380","author":"D Dowell","year":"2019","unstructured":"Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. New Engl J Med 2019;380(24):2285-7. https:\/\/doi.org\/10.1056\/NEJMp1904190","journal-title":"New Engl J Med"},{"key":"6251_CR38","unstructured":"Oliva E, Sandbrink F, Trafton J. What an opioid safety initiative can teach us about using information to improve patient outcomes. In: The BMJ Blog. BMJ. 2020. https:\/\/blogs.bmj.com\/bmj\/2020\/03\/03\/what-an-opioid-safety-initiative-can-teach-us-about-using-information-to-improve-patient-outcomes\/. Accessed June 2, 2020."},{"key":"6251_CR39","doi-asserted-by":"publisher","unstructured":"Fishman MA, Scherer A, Topfer J, Kim PSH. Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids. Pain Med (Malden, Mass). 2019. https:\/\/doi.org\/10.1093\/pm\/pnz197","DOI":"10.1093\/pm\/pnz197"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06251-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T01:03:39Z","timestamp":1636160619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":39,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6251"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06251-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ajay Manhapra, Mark D. Sullivan, R. Ross McLean, and William C. Becker have no conflict of interest or other disclosures to make. Jane C. Ballantyne was a paid consultant in opioid litigation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}